For women navigating the uncertainty of fertility or perimenopause, the standard of care often involves a frustrating translation. A qualitative ovulation test strip offers a yes-or-no answer, but not a number. A blood draw at a clinic provides a precise hormone level, but only for a single moment in time. Oova, a New York-based diagnostics company spun out of Mount Sinai Hospital, is building its business on closing that gap with quantitative, at-home urine tests that are FDA-registered as medical devices.
Founded in 2017 by Dr. Amy Divaraniya, a systems biologist with a PhD from Mount Sinai, Oova sells a kit that measures luteinizing hormone (LH) and progesterone (PdG) levels daily. Users scan the test cartridge with a smartphone app, which uses a proprietary algorithm,trained on data from over 10,000 menstrual cycles,to deliver personalized, numeric readings and fertility window predictions [Femtech Insider, June 2023]. The company’s core bet is that lab-grade quantitative data, not qualitative guesses, will become the new standard for at-home hormone monitoring.
A clinical wedge in a consumer market
Oova’s differentiation starts with its origins. As a hospital spinout, it was built with clinical integration in mind from the start. This is not a consumer gadget company deciding to add health features later. Its FDA registration as a Class I medical device provides a regulatory credibility floor that many direct-to-consumer fertility trackers lack [Perplexity Sonar Pro Brief]. The company reports a network of more than 100 fertility clinics and OB-GYN practices that use the Oova platform to monitor patients remotely, integrating the at-home data directly into clinical workflows.
This clinical wedge is reflected in its investor base, which includes strategic healthcare players like the large fertility clinic network US Fertility and Jefferson Health, alongside venture firms like Spero Ventures and BBG Ventures [TechCrunch, June 2023]. These are not purely consumer-tech bets; they signal belief in Oova’s utility as a tool for providers. For patients, the ability to use HSA/FSA funds to purchase the kits further blurs the line between wellness product and medical device.
The subscription pivot and expansion
In 2023, concurrent with its $10.3 million Series A round, Oova introduced a membership model, shifting from a one-time kit purchase to a recurring revenue service [Perplexity Sonar Pro Brief]. The membership bundles the physical test kits with personalized support and access to a community. This move aligns with the long-term, often multi-cycle nature of fertility journeys and positions the company to build deeper relationships with users.
It also facilitates Oova’s expansion beyond fertility into perimenopause monitoring, a strategic move to address a broader and chronically underserved segment of women’s health. The underlying technology,quantitative tracking of key hormone metabolites,remains consistent, but the clinical context and use case shift from cycle timing to managing a longer-term hormonal transition.
The quantified field of competitors
Oova does not have the at-home hormone tracking space to itself. It operates in a competitive landscape defined by varying approaches to technology and regulation.
| Competitor | Key Differentiator | Regulatory Status |
|---|---|---|
| Inito | Tracks multiple hormones (LH, estrogen, PdG) with a connected device. | FDA-registered. |
| Mira | Analyzes LH and estrogen with a dedicated analyzer, providing numeric values. | FDA-registered. |
| Eli Health | Continuous hormone monitoring via a wearable sensor. | In development. |
| Clearblue | Market-leading qualitative ovulation tests. | FDA-cleared. |
| Proov | Focuses specifically on PdG (progesterone) confirmation post-ovulation. | FDA-registered. |
Oova’s answer to this field rests on three pillars: the depth of its clinical partnerships, the size of its proprietary dataset for algorithm training, and its dual focus on both fertility and perimenopause from a single platform.
The risks in the data
For all its clinical tailwinds, Oova’s path is not without obstacles. The market, while growing, is crowded with well-funded players also pursuing FDA pathways and clinic partnerships. Consumer adoption hinges on convincing users that quantitative data is worth a premium over cheaper, qualitative options, a challenge in a cost-sensitive healthcare environment.
The company’s algorithm is a core asset, but its performance claims, like the ability to accurately predict fertile windows for women with irregular cycles, are based on proprietary data. Independent, peer-reviewed validation of these outcomes would strengthen its position with a skeptical medical community. Furthermore, the shift to a subscription model tests whether users perceive enough ongoing value to pay recurrently after an initial diagnostic phase.
The next twelve months
Oova’s near-term milestones will likely revolve around scaling its clinic network and proving the membership model. Key signals to watch include announced partnerships with major health systems, any published clinical studies using its data, and metrics around subscriber retention. Another funding round may be on the horizon to fuel this expansion, given the capital-intensive nature of hardware-involved healthcare businesses.
The company is ultimately betting on a future where hormone health is managed with continuous, quantitative data, similar to how continuous glucose monitors have transformed diabetes care. For the millions of women experiencing infertility or the transition into perimenopause, the current standard of care is often fragmented and reactionary,relying on infrequent blood tests, subjective symptom tracking, and qualitative home tests that offer limited insight.
Oova’s proposition is to make precise hormone tracking a routine, accessible part of that journey, providing a data stream that both the patient and her doctor can use. Whether that data leads to better outcomes,more successful conceptions, smoother menopausal transitions,is the critical question the next phase of the company’s growth must answer.
Sources
- [Femtech Insider, June 2023] Oova Raises $10.3M in Series A Funding for Its Fertility Tracking Solution | https://femtechinsider.com/oova-series-a/
- [TechCrunch, June 2023] Oova raises $10.3M for its at-home fertility hormone test | https://techcrunch.com/2023/06/27/oova-series-a/
- [Perplexity Sonar Pro Brief] Oova company and product overview
- [Crunchbase] OOVA - Crunchbase Company Profile & Funding
- [oova.life] About Oova | Personalized At-Home Hormone Monitoring
- [FemTech World] Women’s health start-up launches perimenopause hormone kit
- [Forbes, April 2025] Early funding report on Oova